低级别尿路上皮癌的复发节奏随时间自然加速
基于英国西米德兰兹膀胱癌预后计划(BCPP)数据,分析379例G1/G2 pTa中危非肌层浸润性膀胱癌(LG IR-NMIBC)患者,中位随访4.2年(95%CI:3.9-4.8),5年内53%至少复发一次,1年无复发生存率75%、4年50%,第1至第5次序贯复发的中位时间依次为49、19、12、14、10个月。
要点
- 中危非肌层浸润性膀胱癌5年内53%至少复发一次,中位随访4.2年。
- 1年无复发生存率75%,4年无复发生存率50%。
- 第1至第5次序贯复发的中位时间依次为49、19、12、14、10个月。
核心结论
- 超过半数中危非肌层浸润性膀胱癌患者最终会复发,数据提示部分患者复发随时间加速,这一加速可能作为潜在的动力学生物标志物用于指导监测间隔和未来治疗策略。
研究设计与样本
- 利用英国西米德兰兹膀胱癌预后计划(BCPP)参与者的基线和随访数据,评估中危非肌层浸润性膀胱癌参与者的总体复发率和无复发间期,无复发间期采用Kaplan-Meier法计算。
- 共识别379例G1/G2 pTa肿瘤且分类为中危的患者,中位年龄70岁,284/379(75%)为男性,中位随访时间4.2年(95%CI:3.9-4.8)。
主要发现
- 随访5年后,53%的患者至少发生一次复发。
- 1年无复发生存率为75%,4年无复发生存率为50%。
- 第1、2、3、4、5次序贯复发的中位时间分别为49、19、12、14、10个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the cadence of recurrence in patients with low grade intermediate-risk non-muscle invasive bladder cancer (LG IR-NMIBC) based on clinical determinants. We aim to describe patterns in rates of recurrence to better inform surveillance regimens for this chronic, burdensome, and costly disease. METHODS: Using baseline and follow-up data from participants in the West Midlands' (United Kingdom, UK) Bladder Cancer Prognosis Programme (BCPP), we assessed overall recurrence rate and recurrence-free intervals throughout the follow-up period for IR-NMIBC participants. Recurrence-free intervals were calculated using the Kaplan-Meier method. RESULTS: We identified 379 patients with G1/G2 pTa tumors classified as intermediate risk. Median age was 70 and 284/379 (75%) were male. The median follow-up time was 4.2 years (95% CI: 3.9-4.8). After 5 years of follow-up, 53% of patients had at least one recurrence. One-year recurrence-free survival (RFS) was 75% and 4-year RFS was 50%. The median time to or between 1st, 2nd, 3rd, 4th, and 5th sequential recurrences was 49, 19, 12, 14, and 10 months, respectively. CONCLUSION: Over half of patients with IR-NMIBC are destined to recur. Our data suggest that a subset of patients experience acceleration of recurrence over time and that this acceleration may serve as a potential kinetic biomarker for these individuals that could inform surveillance intervals and future treatment strategies.
引用
- Sankin A, Dave P, Cherrill LR, et al. Low-grade Urothelial Carcinoma Recurs at a Tempo that Naturally Accelerates Over Time. Urology. 2024. PMID: 39029806. doi:10.1016/j.urology.2024.07.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。